X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326
https://www.globenewswire.com/news-release/2023/04/20/2650654/0/en/Novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-Kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis.html
https://www.prnewswire.com/news-releases/novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis-301802531.html
https://www.ema.europa.eu/en/documents/overview/kesimpta-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326
https://www.fiercepharma.com/pharma/among-novartis-key-growth-drivers-ms-drug-kesimpta-surges-kisqali-sees-positive-trend-breast
https://www.medpagetoday.com/hematologyoncology/leukemia/99556
https://www.europeanpharmaceuticalreview.com/news/172724/continuous-treatment-kesimpta-rms-neda-3/
https://www.novartis.com/news/media-releases/new-peer-reviewed-research-shows-no-increased-risk-serious-covid-19-infections-kesimpta-ofatumumab-treated-adults-multiple-sclerosis
http://www.pharmatimes.com/news/tecentriq,_kesimpta_lead_latest_smc_decisions_1373053
https://www.novartis.com/news/media-releases/kesimpta-ofatumumab-data-show-long-term-preservation-iggigm-levels-and-no-increased-risk-serious-infections-people-living-multiple-sclerosis
https://www.novartis.us/news/media-releases/kesimpta-ofatumumab-data-aan-showed-reduction-disability-progression-independent
http://www.pharmafile.com/news/575810/novartis-ms-therapy-gains-mhra-and-ec-approval
http://www.pharmatimes.com/news/novartis_bags_eu,_uk_licences_for_ms_therapy_kesimpta_1366541
https://www.pharmaceutical-technology.com/news/ec-novartis-kesimpta-relapsing-multiple-sclerosis/
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-adult-patients-relapsing-multiple-sclerosis
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-adult-patients-relapsing-multiple-sclerosis#:~:text=Basel%2C%20March%2030%2C%202021%20%E2%80%94,by%20clinical%20or%20imaging%20features.
https://www.fiercepharma.com/marketing/novartis-first-dtc-for-multiple-sclerosis-med-kesimpta-proffers-break-from-rms-drama
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kesimpta-ofatumumab-self-administered-treatment-adult-patients-relapsing-multiple-sclerosis
https://www.fiercepharma.com/marketing/roche-looking-for-ocrevus-convenience-boost-snags-fda-nod-for-2-hour-infusion
https://scrip.pharmaintelligence.informa.com/SC143493/Novartis-MS-Drug-Kesimpta-Quick-Out-Of-The-Blocks
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326
https://www.novartis.com/news/media-releases/fda-approves-novartis-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis
http://www.pmlive.com/pharma_news/novartis_builds_its_case_for_novel_ms_treatment_ofatumumab_1346521
https://www.reuters.com/article/us-novartis-fda/u-s-fda-extends-review-of-novartis-multiple-sclerosis-drug-idUSKBN2392ZE?feedType=RSS&feedName=healthNews
https://www.reuters.com/article/us-novartis-fda/u-s-fda-extends-review-of-novartis-multiple-sclerosis-drug-idUSKBN2392ZE
https://www.fiercepharma.com/pharma/novartis-repurposed-leukemia-drug-tops-sanofi-s-aubagio-ms-study-weeks-ahead-fda-verdict
https://www.globenewswire.com/news-release/2020/05/27/2039066/0/en/Novartis-announces-new-late-breaking-ofatumumab-data-at-EAN-demonstrating-robust-efficacy-and-safety-in-the-treatment-of-relapsing-forms-of-multiple-sclerosis-RMS.html
https://www.prnewswire.com/news-releases/roches-ocrevus-continues-to-impress-in-the-eu-with-strong-uptake-in-new-start-and-switch-multiple-sclerosis-patient-segments-but-novartis-mayzent-and-ofatumumab-may-threaten-the-brands-long-term-dominance-301037781.html
http://www.pharmatimes.com/news/ema,_fda_both_accept_filing_of_novartis_ofatumumab_1326919
https://www.clinicaltrialsarena.com/news/celgene-phaseiii-aml-study-results/
https://www.fiercepharma.com/pharma/ectrims-novartis-reinvented-leukemia-drug-bests-sanofi-s-aubagio-slashing-ms-relapses
https://endpts.com/jj-phiii-data-promise-drug-launch-into-crowded-ms-market/
https://www.reuters.com/article/us-novartis-ofatumumab/novartis-ms-drug-cuts-relapse-rate-by-half-compared-to-sanofi-medicine-idUSKCN1VY1EY?feedType=RSS&feedName=healthNews
https://www.clinicaltrialsarena.com/news/novartis-ofatumumab-phase-iii/
https://www.fiercepharma.com/pharma/novartis-repurposed-cancer-drug-arzerra-outpaces-sanofi-s-aubagio-multiple-sclerosis-trial
https://www.thepharmaletter.com/article/novartis-jumps-on-ofatumumab-ms-data
https://www.biospace.com/article/genmab-raises-506-million-in-ipo/
https://endpts.com/novartis-ceo-vas-narasimhan-lines-up-his-late-stage-blockbuster-contenders-mixing-old-favorites-and-add-ons/
http://www.pharmatimes.com/news/genmabnovatis_arzerra_fails_to_hit_nhl_targets_1237014
https://www.fiercepharma.com/pharma/novartis-feeling-heat-from-cll-rivals-pulls-arzerra-outside-u-s
https://endpts.com/ash17-verastems-abbvie-castoff-is-headed-for-the-fda-even-after-missing-overall-survival-goal/
https://globenewswire.com/news-release/2016/12/12/896995/0/en/European-Commission-Grants-Marketing-Authorization-for-Arzerra-ofatumumab-in-combination-with-Fludarabine-and-Cyclophosphamide-in-Relapsed-CLL.html
http://www.reuters.com/article/us-novartis-sale-exclusive-idUSKBN13V1LT
http://www.fiercebiotech.com/story/novartis-stops-phiii-trial-genmabs-arzerra-after-buying-rights-gsk/2016-03-10
http://www.fiercebiotech.com/story/genmabs-lymphoma-project-flops-phase-iii-novartis-holding-bag/2015-11-23
http://www.pharmatimes.com/Article/15-09-21/Genmab_s_Arzerra_gets_six-month_review_for_maintenance_CLL.aspx
Market Place
Share 
